Table 2.
Tumor biological Characteristics
| Primary Tumor (n = 164) |
Metastases (n = 83) |
As Per Clinical Practice* (n = 214) |
|
|---|---|---|---|
| N. (%) | N. (%) | N. (%) | |
| Grade | |||
| 1 | 6 (4.6) | 0 | 6 (3.7) |
| 2 | 49 (38.0) | 11 (47.8) | 67 (40.8) |
| 3 | 74 (57.4) | 12 (52.2) | 91 (55.5) |
| Unknown | 35 | 60 | 50 |
| ER status | |||
| <1% | 30 (18.7) | 8 (9.8) | 33 (15.4) |
| ≥1% | 130 (81.3) | 74 (90.2) | 181 (84.6) |
| Unknown | 4 | 1 | 0 |
| PgR status | |||
| <1% | 49 (30.6) | 30 (36.6) | 75 (35.0) |
| ≥1% | 111 (69.4) | 52 (63.4) | 139 (65.0) |
| Unknown | 4 | 1 | 0 |
| <20% | 81 (50.6) | 41 (50.0) | 113 (52.8) |
| ≥20% | 79 (49.4) | 41 (50.0) | 101 (47.2) |
| Unknown | 4 | 1 | 0 |
| Ki67 status | |||
| <20% | 75 (47.8) | 48 (62.3) | 113 (53.6) |
| ≥20% | 82 (52.2) | 29 (37.7) | 98 (46.4) |
| Unknown | 7 | 6 | 3 |
| HER2 status | |||
| Negative | 100 (63.7) | 71 (88.7) | 152 (71.4) |
| Positive | 57 (36.3) | 9 (11.3) | 61 (28.6) |
| Unknown | 7 | 3 | 1 |
| AR status | |||
| <1% | 28 (17.1) | 22 (26.5) | 46 (21.5) |
| ≥1% | 136 (82.9) | 61 (73.5) | 168 (78.5) |
| Unknown | 0 | 0 | 0 |
| <10% | 33 (20.1) | 33 (39.8) | 62 (29.0) |
| ≥10% | 131 (79.9) | 50 (60.2) | 152 (71.0) |
*
Clinical practice: biomarker expression measured in metastases (when a biopsy was performed on metastases) or in primary tumors (when biopsy on metastases had not been performed).